Koninklijke Philips NV（PHG）の財務PHGKoninklijke Philips NV

Koninklijke Philips N.V. (PHG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnosis & Treatment, accounting for 47.8% of total sales, equivalent to $2.42B. Other significant revenue streams include Connected Care and Personal Health. Understanding this composition is critical for investors evaluating how PHG navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Koninklijke Philips N.V. maintains a gross margin of 49.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.43%, while the net margin is 8.85%. These profitability ratios, combined with a Return on Equity (ROE) of 10.15%, provide a clear picture of how effectively PHG converts its operational activities into shareholder value.

In the context of the broader market, PHG competes directly with industry leaders such as LH and SOLV. With a market capitalization of $26.67B, it holds a leading position in the sector. When comparing efficiency, PHG's gross margin of 49.31% stands against LH's 27.71% and SOLV's 58.62%. Such benchmarking helps identify whether Koninklijke Philips N.V. is trading at a premium or discount relative to its financial performance.

Philips has shown a gross margin improvement to 49.31% in Q2 2026, indicating better cost management and profitability. The company reported a 4% increase in comparable sales for Q2 2026, reflecting strong market performance.